



Prior Authorization Approval Criteria

Cambia (diclofenac)

Generic name:	diclofenac
Brand name:	Cambia
Medication class:	non-steroidal anti-inflammatory drug
FDA-approved uses:	acute treatment of migraine attacks with or without aura.
Available dosage forms:	50mg in a soluble powder
Usual dose:	One 50mg packet for the acute treatment of migraine emptied into 1-2 ounces of water, mix well and drink immediately. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals. The safety and effectiveness of a second dose have not been established.
Approximate monthly cost: (based on AWP 2010)	\$23.87/ 50mg packet
Duration of therapy:	Indefinite

Criteria for use *(bullet points below are all inclusive unless otherwise noted):*

- The indicated diagnosis (including any applicable labs and /or tests) and medication usage must be supported by documentation from the patient's medical records.
- Patient has clinically documented migraine headaches.
- Patient is 18 years of age or older.
- Patient has failed/intolerant to at least two FCHP preferred triptan alternatives such as Imitrex, Maxalt, Frova, Relpax, Axert, or Zomig.
- If the patient has a contraindication to the use of triptans then they must have failed or be intolerant to at least one other liquid form of NSAIDs such as meloxicam, indomethacin, ibuprofen or naproxen.
- Patient is not taking Cambia chronically everyday.
- Quantity limit of 4 packets/month.

Contraindication:

- Known hypersensitivity to diclofenac or NSAIDs
- Pre-existing asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery.

Not approved if:

- Being used for prophylaxis of migraines
- Patient has any contraindications to the use of Cambia.

FCHP Pharmacy and Therapeutics Committee approval: _____

Date: _____

Adopted: 12/08/10